Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Gabrielle Meyers, Mehdi Hamadani, Michael Martens, Haris Ali, Patrice Chevallier, Hannah Choe, Andrew C. Harris, Ernst Holler, Eric van Hooren, Willem Klaassen, Eric Leifer, Ypke van Oosterhout, Lia Perez, Iskra Pusic, Matthias Stelljes, Walter van der Velden, Emanuele Ammatuna, David Beauvais, Jérôme Cornillon, Richard T. MaziarzJohannes Schetelig, Jennifer Romeril, Margaret L. MacMillan, John E. Levine, Gérard Socié

Research output: Contribution to journalLetterpeer-review

2 Scopus citations
Original languageEnglish (US)
Pages (from-to)1416-1418
Number of pages3
JournalBone marrow transplantation
Volume58
Issue number12
DOIs
StatePublished - Dec 2023

Bibliographical note

Funding Information:
Support for this study was provided by grants U10HL069294 and U24HL138660 to the Blood and Marrow Transplant Clinical Trials Network from the National Heart, Lung, and Blood Institute and the National Cancer Institute along with contributions by Xenikos BV. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

PubMed: MeSH publication types

  • Letter

Cite this